Replimune Group (NASDAQ:REPL) Shares Up 4.9%

Shares of Replimune Group, Inc. (NASDAQ:REPL) rose 4.9% on Friday . The stock traded as high as $9.00 and last traded at $8.94. Approximately 448,035 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 1,333,663 shares. The stock had previously closed at $8.52.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Barclays lifted their price objective on Replimune Group from $13.00 to $17.00 and gave the company an “overweight” rating in a report on Friday, June 7th. HC Wainwright boosted their price target on shares of Replimune Group from $12.00 to $17.00 and gave the company a “buy” rating in a report on Friday, June 7th. Finally, Wedbush reiterated an “outperform” rating and set a $16.00 price objective on shares of Replimune Group in a research note on Thursday, June 6th.

Replimune Group Stock Performance

The business has a 50-day moving average of $6.84 and a two-hundred day moving average of $7.60. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.72 and a quick ratio of 10.72. The company has a market cap of $552.78 million, a P/E ratio of -2.67 and a beta of 1.15.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Thursday, May 16th. The company reported ($0.82) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.04. On average, sell-side analysts predict that Replimune Group, Inc. will post -3.31 EPS for the current fiscal year.

Insider Buying and Selling at Replimune Group

In other news, COO Colin Love sold 17,615 shares of the company’s stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $113,969.05. Following the transaction, the chief operating officer now directly owns 777,345 shares of the company’s stock, valued at $5,029,422.15. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, CEO Sushil Patel sold 20,194 shares of Replimune Group stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $6.47, for a total value of $130,655.18. Following the completion of the sale, the chief executive officer now directly owns 212,014 shares in the company, valued at approximately $1,371,730.58. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Colin Love sold 17,615 shares of the business’s stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $6.47, for a total transaction of $113,969.05. Following the sale, the chief operating officer now directly owns 777,345 shares in the company, valued at approximately $5,029,422.15. The disclosure for this sale can be found here. Insiders sold a total of 107,598 shares of company stock worth $712,516 over the last three months. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Replimune Group

Several institutional investors and hedge funds have recently made changes to their positions in REPL. Alps Advisors Inc. raised its stake in Replimune Group by 2.6% in the 3rd quarter. Alps Advisors Inc. now owns 43,550 shares of the company’s stock worth $745,000 after acquiring an additional 1,083 shares during the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Replimune Group by 6.1% in the fourth quarter. Harbor Capital Advisors Inc. now owns 32,311 shares of the company’s stock valued at $272,000 after purchasing an additional 1,844 shares during the period. Exchange Traded Concepts LLC increased its holdings in shares of Replimune Group by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 7,837 shares of the company’s stock valued at $66,000 after purchasing an additional 1,988 shares during the period. Tower Research Capital LLC TRC raised its stake in shares of Replimune Group by 236.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,207 shares of the company’s stock worth $35,000 after purchasing an additional 2,958 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Replimune Group by 72.8% during the first quarter. China Universal Asset Management Co. Ltd. now owns 11,808 shares of the company’s stock worth $96,000 after purchasing an additional 4,975 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.